Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 12/20 | 0.35 |
| ▸ | MMP3 | P08254 | 6/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | FCER2 | P06734 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709581 | 0.93 | CTSS (0.35) | CTSSCTSKMMP2MMP3MMP1 | |
| SCHEMBL9556176 | 0.90 | MMP2 (0.35) | CTSSCTSKMMP2MMP3MMP1 | |
| SCHEMBL9556465 | 0.87 | MMP2 (0.33) | CTSSCTSKMMP2MMP3MMP1 | |
| SCHEMBL7322606 | 0.87 | CTSS (0.40) | CTSSCTSKMMP2MMP3MMP1 | |
| SCHEMBL6349373 | 0.80 | HRH4 (0.34) | MMP2MMP3 | |
| SCHEMBL5709641 | 0.78 | LTB4R (0.41) | — | |
| SCHEMBL5709642 | 0.77 | MMP1 (0.38) | CTSSCTSKMMP2MMP3MMP1 | |
| SCHEMBL7322599 | 0.77 | MMP1 (0.39) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL9555901 | 0.75 | CTSK (0.46) | CTSSCTSKMMP2MMP3MMP1 | |
| SCHEMBL5709603 | 0.74 | CTSS (0.39) | CTSSCTSKMMP2MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| US-5229420-A | Renin inhibitor | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| US-4900746-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1990-02-13 | — | — | US | disclosed |
| WO-1990000051-A1 | ETHEREAL N-TERMINAL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | CTSS 127/4885CTSK 551/4885MMP2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.